Development and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2020	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
BARDA Agreement
Licenses Agreements [Line Items]
Additional committed fund receivable						$ 3,500,000
Committed fund receivable			$ 185,500,000
Reduction in committed fund receivable			8,800,000
Committed fund receivable			270,200,000
Receivable of billed and unbilled amounts			2,400,000		$ 5,600,000
BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company			1,400,000
FDA Agreement
Licenses Agreements [Line Items]
Contract agreement term		5 years
Total potential contract value		$ 11,100,000
DoD and IBAS Program Agreement | Minimum
Licenses Agreements [Line Items]
Total contract value	$ 9,100,000
DoD and IBAS Program Agreement | Maximum
Licenses Agreements [Line Items]
Total contract value	$ 17,800,000
2024 BARDA Agreement
Licenses Agreements [Line Items]
Committed fund receivable				$ 32,100,000
Committed fund receivable			188,400,000
2024 BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company			60,100,000
Accounts Receivable, Net | FDA Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			500,000		500,000
Accounts Receivable, Net | DoD and IBAS Program Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			1,000,000		3,700,000
Accounts Receivable, Net | 2024 BARDA Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			100,000
Deferred Revenue | DoD and IBAS Program Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			$ 500,000		$ 1,500,000